Members of the Innovative Pharmaceutical Initiative (iF!) recorded at least HRK 124.5 million* in transferred value in 2020 to healthcare organisations and healthcare professionals, as well as investments in research and development, which enable patients to access the latest therapies and educate physicians about new and effective treatment methods.

Of the total amount, the innovative pharmaceutical industry in Croatia invested HRK 28.7 million in research and development last year, which is almost HRK 5 million more than in 2019. At least HRK 45.8 million in value was transferred to healthcare professionals and at least HRK 49.9 million to healthcare organisations, i.e. 40 percent of the total transfer. In line with data‑protection regulations, 25.3 percent of physicians voluntarily provided their data for individual publication of value‑transfer information.

Data on transfers of value to physicians and healthcare organisations were published by iF! member companies, by 30 June, in accordance with the requirements of the EFPIA Disclosure Code, which has been the practice of the innovative pharmaceutical industry for six consecutive years in more than 30 countries. The innovative pharmaceutical industry is the first industry in the world to publish value‑transfer data publicly, thus contributing to transparency in cooperation between the public and private sectors, as well as to a better understanding of the industry’s relationships with healthcare professionals and organisations.

With these funds, the innovative pharmaceutical industry in Croatia has, for example, enabled the implementation of a number of valuable projects by various healthcare organizations through sponsorships and donations, thereby contributing to the improvement of public health in the Republic of Croatia. In addition to the professional development of physicians, the collaboration between the industry and healthcare professionals also involves participation in medical and educational meetings, where physicians provide their expertise, time, and work, for which they receive fair compensation. Research and development refer to the processes of collecting data on the efficacy and safety of specific medicines or medical procedures, and are conducted through clinical studies and collaboration with healthcare organizations, healthcare professionals, and patients. In addition to the transfer of value itself, research and development processes also provide additional value through free medicines, as well as the education of physicians on new and more effective treatment methods. Recognising the value and contribution of patient organisations’ work in the healthcare system, the innovative pharmaceutical industry supported the activities of these organisations with a total of HRK 6 million.